Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | FEN1 | P39748 | 2/20 | 0.47 |
| ▸ | AKT1 | P31749 | 3/20 | 0.46 |
| ▸ | AKT2 | P31751 | 3/20 | 0.46 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.44 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21806028 | 0.98 | LRRK2 (0.50) | LRRK2MAP4K4FEN1AKT1AKT2 | |
| SCHEMBL29859640 | 0.79 | MKNK1 (0.44) | LRRK2FEN1AKT1AKT2MKNK1 | |
| SCHEMBL31403817 | 0.79 | LRRK2 (0.46) | LRRK2FEN1AKT1AKT2AKT3 | |
| SCHEMBL19028096 | 0.79 | AKT1 (0.46) | LRRK2FEN1AKT1AKT2AURKA | |
| SCHEMBL30608796 | 0.79 | AKT1 (0.46) | LRRK2FEN1AKT1AKT2AURKA | |
| SCHEMBL22736242 | 0.79 | AURKA (0.51) | LRRK2FEN1AKT1AKT2AURKA | |
| SCHEMBL21359446 | 0.77 | KDM4E (0.46) | LRRK2AKT1AKT2AURKAAURKB | |
| SCHEMBL15196298 | 0.76 | AKT1 (0.40) | LRRK2FEN1AKT1AKT2AKT3 | |
| SCHEMBL20468195 | 0.76 | AKT2 (0.55) | LRRK2FEN1AKT1AKT2AURKA | |
| SCHEMBL587812 | 0.76 | MEN1 (0.49) | FEN1AURKABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024263801-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING OVARIAN CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263804-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING KIDNEY CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263963-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING HEAD AND NECK CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| US-11034685-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2021-06-15 | — | — | US | disclosed |
| US-20200299287-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORPORATION (CA) | 2020-09-24 | — | — | US | disclosed |
| WO-2019000237-A1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-8841327-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| US-8841327-B2 | Heterocycles substituted pyridine derivatives and antifungal agent containing thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| EP-2628738-B1 | Heterocyclic substituted pyridine derivatives and antifungal agent containing same | EISAI R&D MAN CO LTD (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20130281455-A1 | Phenylpyri(mi)dinylazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-7691882-B2 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| EP-2141171-A1 | PYRIDINE DERIVATIVE SUBSTITUTED WITH HETEROCYCLE AND PHOSPHONOAMINO AND ANTIFUNGAL AGENT CONTAINING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1944303-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1944303-A1 | PYRIDINE DERIVATIVE SUBSTITUTED BY HETEROCYCLE AND FUNGICIDE CONTAINING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281455-A1 | Phenylpyri(mi)dinylazoles | PIR, PIN4, PNN | LRRK2 4282/4885MAP4K4 1413/4885FEN1 2151/4885 |
| US-20200299287-A1 | AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | MAP3K6, MAP3K5, MERTK | LRRK2 439/4885MAP4K4 61/4885FEN1 2039/4885 |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | ERG28, H1-2, H1-3 | LRRK2 2060/4885MAP4K4 630/4885FEN1 1290/4885 |
| US-11034685-B2 | Aminopyridine derivatives as TAM family kinase inhibitors | MAP3K6, MAP3K5, MERTK | LRRK2 439/4885MAP4K4 61/4885FEN1 2039/4885 |
| US-20070105904-A1 | 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells | GPI, ERG28, MAN2A1 | LRRK2 2339/4885MAP4K4 2997/4885FEN1 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.